Astrazeneca (AZN.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec25

AstraZeneca's Vilumatin Approved in China for ATTRv-PN Treatment

09:22

AstraZeneca's Enhertu Approved for New Indication

08:41

DS-8201 Receives New Indication Approval in China for Previously Treated HR+, HER2-Low Advanced Breast Cancer

05:45

AstraZeneca and JABYO Enter into a License Agreement, Jacada Shares Under Pressure

01:04

Dec24

AstraZeneca's GefeRulimab Filed for Marketing Authorization to Treat Generalized Myasthenia Gravis

05:55

Dec22

KDA and AstraZeneca Partner to Promote NGS Diagnostic Tests for Metastatic Breast Cancer

16:01

Schedules & Filings

Schedules

Filings

Feb10

Earning Release(EST)

FY2025 Q4 Earning Release

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 15.19 B, Net Income 2.533 B, EPS 0.81

AstraZeneca PLC (AZN.US) Q3 2025 Earnings Conference Call

Sep8

Distribution Plan(EST)

Cash dividend 0.515 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change